Evidence map›Paper›PMID 34980890›Full record

ReviewNature reviews. Nephrology2022

Patient-centred approaches for the management of unpleasant symptoms in kidney disease.

Kamyar Kalantar-Zadeh, Mark B Lockwood, Connie M Rhee, Ekamol Tantisattamo, Sharon Andreoli, Alessandro Balducci, Paul Laffin, Tess Harris, Richard Knight, Latha Kumaraswami and 8 more

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06257134 (Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients, With Results Notification to Teams. A Cluster Randomised Controlled Trial Nested in a National Registry F-SWIFT), which is not on this map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
25.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06257134 narecruitingnot on this mapstarted 2026, after this paper: background citation

Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients, With Results Notification to Teams. A Cluster Randomised Controlled Trial Nested in a National Registry F-SWIFT (French Symptom Monitoring WIth Feedback Trial)

TypeinterventionalSponsorCentral Hospital, Nancy, FranceRan2026 to 2026Enrolled2,293ConditionsEnd Stage Renal DiseaseArmsNo systematic monitoring of symptoms, Systematic monitoring of symptoms
3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 187 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Blood Flow Restriction Training in Hemodialysis Patients: Clinical Benefits, Challenges, and Future Perspectives.Hemodialysis international. International Symposium on Home Hemodialysis · 2026
    Review
  19. Article
  20. Observational

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 8 countries.

Kamyar Kalantar-ZadehThe International Federation of Kidney Foundation - World Kidney Alliance (IFKF-WKA), Mexico City, Mexico. kkz@uci.edu.ORCID http://orcid.org/0000-0002-8666-0725
Mark B LockwoodDepartment of Behavioral Health Science, University of Illinois at Chicago, College of Nursing, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-2534-8583
Connie M RheeDivision of Nephrology and Hypertension and Kidney Transplantation, University of California, Irvine, Irvine, CA, USA.
Ekamol TantisattamoDivision of Nephrology and Hypertension and Kidney Transplantation, University of California, Irvine, Irvine, CA, USA.
Sharon AndreoliJames Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Alessandro BalducciItalian Kidney Foundation, Rome, Italy.
Paul LaffinWorld Kidney Day Office, Brussels, Belgium.
Tess HarrisPolycystic Kidney Disease Charity, London, UK.ORCID http://orcid.org/0000-0003-3659-7438
Richard KnightAmerican Association of Kidney Patients, Tampa, FL, USA.
Latha KumaraswamiTanker Foundation, Chennai, India.
Vassilios LiakopoulosDivision of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0002-7564-2724
Siu-Fai LuiThe International Federation of Kidney Foundation - World Kidney Alliance (IFKF-WKA), Mexico City, Mexico.
Sajay KumarTanker Foundation, Chennai, India.
Maggie NgThe International Federation of Kidney Foundation - World Kidney Alliance (IFKF-WKA), Mexico City, Mexico.
Gamal SaadiNephrology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt.
Ifeoma UlasiRenal Unit, Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla, Enugu, Nigeria.
Allison TongSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
Philip Kam-Tao LiDepartment of Medicine and Therapeutics, Carol & Richard Yu PD Research Centre, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China. philipli@cuhk.edu.hk.ORCID http://orcid.org/0000-0001-9879-8388
University of California, Irvine · USAmerican Association of Kidney Patients · USAristotle University of Thessaloniki · GRCairo University · EGChinese University of Hong Kong · HKKidney Care UK · GBNational Kidney Foundation · USRiley Hospital for Children · USThe University of Sydney · AUUniversity of Illinois Chicago · USUniversity of Nigeria Teaching Hospital · NG

Funding

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis PatientsR01DK122767 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RHEE, CONNIE MEEYOUNG · 2019 to 2023
$3.3M
Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis ApproachesR01DK124138 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KALANTAR-ZADEH, KAMYAR, RHEE, CONNIE MEEYOUNG · 2020 to 2024
$2.9M
Transition of Care in CKD (TC-CKD)U01DK102163 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI JACOBSEN, STEVEN J, KALANTAR-ZADEH, KAMYAR · 2014 to 2018
$2.8M
MALNUTRITION, DIET AND RACIAL DISPARITIES IN CKDK24DK091419 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI KALANTAR-ZADEH, KAMYAR · 2011 to 2020
$1.8M
Novel Saliva-based Renal Function Test PlatformR44DK116383 · NIDDK · INTELLIGENT OPTICAL SYSTEMS, INC. · PI KALANTAR-ZADEH, KAMYAR, NGUYEN, TRONG · 2018 to 2020
$1.7M
A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis PatientsR03DK114642 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI RHEE, CONNIE MEEYOUNG · 2017 to 2018
$155k
NIDDK NIH HHS K24 DK091419NIDDK NIH HHS R01 DK122767NIDDK NIH HHS R01 DK124138NIDDK NIH HHS R03 DK114642NIDDK NIH HHS R44 DK116383NIDDK NIH HHS U01 DK102163
6 · The paper itself

Abstract

Patients with chronic kidney disease (CKD) frequently experience unpleasant symptoms. These can be gastrointestinal (constipation, nausea, vomiting and diarrhoea), psychological (anxiety and sadness), neurological (lightheadedness, headache and numbness), cardiopulmonary (shortness of breath and oedema), dermatological (pruritus and dry skin), painful (muscle cramps, chest pain and abdominal pain) or involve sexual dysfunction, sleep disorders and fatigue. These symptoms often occur in clusters, with one of them as the lead symptom and others as secondary symptoms. Uraemic toxins (also called uremic toxins) are often considered to be the main cause of CKD-associated symptom burden, but treatment of uraemia by dialysis often fails to resolve them and can engender additional symptoms. Indeed, symptoms can be exacerbated by comorbid conditions, pharmacotherapies, lifestyle and dietary regimens, kidney replacement therapy and ageing. Patients with kidney disease, including those who depend on dialysis or transplantation, should feel actively supported in their symptom management through the identification and targeting of unpleasant symptoms via a tailored palliative care approach. Such an approach may help minimize the burden and consequences of kidney disease, and lead to improved patient outcomes including health-related quality of life and better life participation.

Indexed as

Renal Insufficiency, ChronicUremiaFatigueHumansQuality of LifeRenal Dialysis

Identifiers

PMID34980890
OpenAlexW4205762302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.